IONS Quote, Financials, Valuation and Earnings

Biogen has a net margin of -104.98% compared to Ionis Pharmaceuticals's net margin of 15.76%. Ionis Pharmaceuticals's return on equity of -93.21% beat Biogen's return on equity of 10.52%.

Ionis Pharmaceuticals has a consensus price target of $61.36, signalling upside risk potential of 70.87%. On the other hand Biogen has an analysts' consensus of $244.02 which suggests that it could grow by 61.27%. Given that Ionis Pharmaceuticals has higher upside potential than Biogen, analysts believe Ionis Pharmaceuticals is more attractive than Biogen.

Ionis Pharmaceuticals has a beta of 0.349, which suggesting that the stock is 65.148% less volatile than S&P 500. In comparison Biogen has a beta of -0.081, suggesting its less volatile than the S&P 500 by 108.074%.

Ionis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

Ionis Pharmaceuticals quarterly revenues are $133.8M, which are smaller than Biogen quarterly revenues of $2.5B. Ionis Pharmaceuticals's net income of -$140.5M is lower than Biogen's net income of $388.5M. Notably, Ionis Pharmaceuticals's price-to-earnings ratio is -- while Biogen's PE ratio is 13.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals is 6.53x versus 2.30x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Biomarin Pharmaceutical has a net margin of -104.98% compared to Ionis Pharmaceuticals's net margin of 14.23%. Ionis Pharmaceuticals's return on equity of -93.21% beat Biomarin Pharmaceutical's return on equity of 6.29%.

Ionis Pharmaceuticals has a consensus price target of $61.36, signalling upside risk potential of 70.87%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $98.08 which suggests that it could grow by 46.63%. Given that Ionis Pharmaceuticals has higher upside potential than Biomarin Pharmaceutical, analysts believe Ionis Pharmaceuticals is more attractive than Biomarin Pharmaceutical.

Ionis Pharmaceuticals has a beta of 0.349, which suggesting that the stock is 65.148% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.295, suggesting its less volatile than the S&P 500 by 70.544%.

Ionis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Ionis Pharmaceuticals quarterly revenues are $133.8M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $745.7M. Ionis Pharmaceuticals's net income of -$140.5M is lower than Biomarin Pharmaceutical's net income of $106.1M. Notably, Ionis Pharmaceuticals's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 40.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals is 6.53x versus 4.77x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -104.98% compared to Ionis Pharmaceuticals's net margin of 0.7%. Ionis Pharmaceuticals's return on equity of -93.21% beat Moderna's return on equity of -17.44%.

Ionis Pharmaceuticals has a consensus price target of $61.36, signalling upside risk potential of 70.87%. On the other hand Moderna has an analysts' consensus of $127.09 which suggests that it could grow by 84.87%. Given that Moderna has higher upside potential than Ionis Pharmaceuticals, analysts believe Moderna is more attractive than Ionis Pharmaceuticals.

Ionis Pharmaceuticals has a beta of 0.349, which suggesting that the stock is 65.148% less volatile than S&P 500. In comparison Moderna has a beta of 1.582, suggesting its more volatile than the S&P 500 by 58.238%.

Ionis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Ionis Pharmaceuticals quarterly revenues are $133.8M, which are smaller than Moderna quarterly revenues of $1.9B. Ionis Pharmaceuticals's net income of -$140.5M is lower than Moderna's net income of $13M. Notably, Ionis Pharmaceuticals's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals is 6.53x versus 3.07x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -104.98% compared to Ionis Pharmaceuticals's net margin of 36.03%. Ionis Pharmaceuticals's return on equity of -93.21% beat Regeneron Pharmaceuticals's return on equity of 17.19%.

Ionis Pharmaceuticals has a consensus price target of $61.36, signalling upside risk potential of 70.87%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $1,053.08 which suggests that it could grow by 47.82%. Given that Ionis Pharmaceuticals has higher upside potential than Regeneron Pharmaceuticals, analysts believe Ionis Pharmaceuticals is more attractive than Regeneron Pharmaceuticals.

Ionis Pharmaceuticals has a beta of 0.349, which suggesting that the stock is 65.148% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.084, suggesting its less volatile than the S&P 500 by 91.622%.

Ionis Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ionis Pharmaceuticals pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Ionis Pharmaceuticals quarterly revenues are $133.8M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3.7B. Ionis Pharmaceuticals's net income of -$140.5M is lower than Regeneron Pharmaceuticals's net income of $1.3B. Notably, Ionis Pharmaceuticals's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 17.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ionis Pharmaceuticals is 6.53x versus 5.92x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.